Ömrüm Uzun

Sie wurde am 13. Januar 1960 im Landkreis Susurluk in Balıkesir geboren. Mit zehn Jahren zog sie nach Ankara und schloss 1971 die Sarar-Grundschule ab. Nachdem sie das im selben Jahr begonnene Atatürk-Anadolu-Gymnasium in Ankara 1978 als Jahrgangsbeste abgeschlossen hatte, nahm sie das Studium an der Medizinischen Fakultät der Universität Ankara auf. Das Medizinstudium schloss sie 1984 als Zweitbeste ab und leistete ihren Pflichtdienst in der Tuberkulose-Beratungsstelle Nr. 7 in Ankara. Von 1986 bis 1990 absolvierte sie die Facharztausbildung in Innerer Medizin in der Abteilung für Innere Medizin der Medizinischen Fakultät der Universität Hacettepe und begann im selben Jahr in der Einheit für Infektionskrankheiten zu arbeiten. 1993 wurde sie Assistenzprofessorin. Von 1993 bis 1995 arbeitete sie zwei Jahre lang in den Vereinigten Staaten von Amerika in Houston am M.D. Anderson Cancer Center in der Forschungseinheit für Mykologie und Pilzinfektionen als „Post-doctoral Fellow“. 1995 wurde sie Assoz. Professorin, 2002 erhielt sie den Professorentitel. Dr. Uzun hat 41 auf internationalen Kongressen vorgestellte Beiträge, 46 in internationalen Zeitschriften veröffentlichte Artikel sowie 25 inländische und 2 ausländische Buchkapitel vorzuweisen.

Dr. Uzun hat eine Tochter. Ihre außermedizinischen Interessen sind das Hören klassischer Musik sowie das Schreiben von Gedichten und Romanen (auf Englisch und Türkisch).

1. Eleven-Year Trends in Antimicrobial Resistance and Isolation Rates per 1000 Patient-Days of Key Gram-Positive and Gram-Negative Bacteria in a Tertiary Care Hospital in Türkiye (2014–2024)Demirtaş R. B., METAN G., Dizman G. T., HAZIROLAN G., AKOVA M., UZUN Ö.Infectious Diseases and Clinical Microbiology, cilt.8, sa.5, ss.446-460, 2026 (ESCI, Scopus, TRDizin)
2. Does Antibiotic Choice for Prophylaxis Affect the Outcome of Wound Infections in Earthquake Victims?AKA N., IŞIK M. C., PAMUKÇU T., TELLİ DİZMAN G., BATUR A., KAYA E. K., et al.Infectious Diseases and Clinical Microbiology, cilt.8, sa.4, ss.402-412, 2026 (ESCI, Scopus, TRDizin)
3. Posaconazole Therapeutic Drug Monitoring in Daily Practice: A Single-Center AnalysisBalaban U., Kara E., Pinar A., Gülmez Kıvanç D., Karakulak E. A., Akdagli S. A., et al.INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, cilt.42, ss.818-825, 2026 (SCI-Expanded, Scopus)
4. Clinical pharmacist-led implementation of an intravenous-to-oral antimicrobial switch protocol: A prospective Quasi-experimental studyYumrucu F. G., KARA E., YUMRUKAYA L., ZENGİN H. Y., YEĞENOĞLU S., İNKAYA A. Ç., et al.Journal of Infection and Chemotherapy, cilt.32, sa.3, 2026 (SCI-Expanded, Scopus)
5. COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?Aydın D., KARCIOĞLU O., UZUN Ö.Clinical Infectious Diseases, cilt.82, sa.1, 2026 (SCI-Expanded, Scopus)
6. Towards precision antibiotic therapy: predictors and outcomes of meropenem target attainmentAKMAN AR E. D., KARA E., Karadoğan E., ÖZDEDE M., PINAR A., UZUN Ö., et al.European Journal of Hospital Pharmacy, 2026 (SCI-Expanded, Scopus)
7. Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment Hematolojik Maligniteli Hastalarda Antifungal Yönetim: Primer Profilaksi, Ampirik Tedavi ve Tanı Odaklı YaklaşımlarÖZKOCAMAN V., ALP KIRKIZLAR T., METAN G., UZUN Ö., PINAR İ. E., ÖZKALEMKAŞ F., et al.Turkish Journal of Hematology, cilt.43, sa.3, ss.250-261, 2026 (SCI-Expanded, Scopus, TRDizin)
8. The impact of an institutional sepsis guideline on selecting appropriate empirical treatment in patients with carbapenem-resistant gram-negative bacilli bacteremiaUzar H., Karadoğan E., SERTÇELİK A., Dizman G. T., HAZIROLAN G., UZUN Ö., et al.European Journal of Clinical Microbiology and Infectious Diseases, cilt.45, sa.1, ss.145-155, 2026 (SCI-Expanded, Scopus)
9. CLINICAL PHARMACISTS' ASSESSMENT OF DRUG-RELATED PROBLEMS IN PATIENTS USING ANTIMICROBIALSGeridonmez O., KARA E., UZUN Ö., DEMİRKAN S. K.INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, cilt.47, sa.2, ss.520-521, 2025 (SCI-Expanded, Scopus)
10. EVALUATION OF ANTIMICROBIAL DOSES USING POINT PREVALENCE AT DIFFERENT TIME POINTSKucukyildiz B., KARA E., UZUN Ö.INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, cilt.47, sa.2, ss.505, 2025 (SCI-Expanded, Scopus)
11. INTRAVENOUS-TO-ORAL SWITCH IN ANTIMICROBIAL THERAPY: A SINGLE-CENTER, OBSERVATIONAL STUDYYumrucu F. G., KARA E., İNKAYA A. Ç., METAN G., UZUN Ö.INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, cilt.47, sa.2, ss.499, 2025 (SCI-Expanded, Scopus)
12. Impact of Aspergillus PCR on the management of invasive aspergillosis: A tertiary care hospital experience during the COVID-19 pandemicIŞIK M. C., METAN G., ALP A., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., UZUN Ö.DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, cilt.111, sa.3, 2025 (SCI-Expanded, Scopus)
13. Invasive fungal infections in patients with acute leukemia: A retrospective cohort study at a tertiary-care hospitalAlkan A., BÜYÜKAŞIK Y., UZUN Ö., DEMİR A. U., ÇÖPLÜ L.MEDICINE, cilt.103, sa.40, 2024 (SCI-Expanded, Scopus)
14. Effect of inflammation on voriconazole levels in patients with invasive pulmonary aspergillosisBAKIR EKİNCİ P., BAYRAKTAR ALKAN İ., ER A. G., Pinar A., İNKAYA A. Ç., DEMİRKAN S. K., et al.JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.18, sa.10, ss.1617-1624, 2024 (SCI-Expanded, Scopus)
15. The impact of hospital-specific guidelines on carbapenem use and patient outcomes in a setting for high endemicity with multidrug-resistant gram-negative bacilliBOŞNAK C., Findik S. B., Atay M., Fakhouri W., Babazade S., Karadogan E., et al.ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, cilt.4, sa.1, 2024 (ESCI, Scopus)
16. Cefepime Related Neurological Complications in a Dialysis Patient: A Case ReportBAYRAKTAR ALKAN İ., Muderrisoglu T., KARA E., UZUN Ö.FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, cilt.29, sa.3, ss.398-402, 2024 (ESCI, TRDizin)
17. An Institutional Febrile Neutropenia Protocol Improved the Antibacterial Treatment and Encouraged the Development of a Computerized Clinical Decision Support SystemTAŞ Z., METAN G., TELLİ DİZMAN G., Yavuz E., DİZDAR Ö., BÜYÜKAŞIK Y., et al.ANTIBIOTICS-BASEL, cilt.13, sa.9, 2024 (SCI-Expanded, Scopus)
18. The Impact of Reporting the Same-Day Identification and Antibiotic Susceptibility Test Results on the Treatment of Bloodstream InfectionsDEMİR M., TELLİ DİZMAN G., HAZIROLAN G., UZUN Ö., METAN G.INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, cilt.6, sa.2, ss.123-132, 2024 (ESCI, Scopus, TRDizin)
19. Lomentospora prolificans Fungemia in a Patient With T-Cell Large Granular Leukemia: A Rare Pathogen in TürkiyeKAYA E. K., TAŞTEKİN M. B., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., TOPELİ İSKİT A., UZUN Ö.MIKROBIYOLOJI BULTENI, cilt.58, sa.2, ss.209-216, 2024 (SCI-Expanded, Scopus, TRDizin)
20. Invasive fungal rhinosinusitis by Fusarium proliferatum/annulatum in a patient with acute myeloid leukemia: A case report and review of the literatureCaliskan Z. C., Karahan G., Koray N., GÖKÇINAR Y., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., et al.Journal of Medical Mycology, cilt.34, sa.1, 2024 (SCI-Expanded, Scopus)
21. Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultationsÖzden A., Dalgıç B., DEMİR M., HAZIROLAN G., UZUN Ö., METAN G.Journal of Chemotherapy, cilt.36, sa.3, ss.190-197, 2024 (SCI-Expanded, Scopus)
22. Initial Empirical Antibiotic Treatment in Covid-19 Patients is Related with Excess Adverse Drug Reactions Without Clinical BenefitBAKIR EKİNCİ P., KARA E., TELLİ DİZMAN G., SÖNMEZER M. Ç., İNKAYA A. Ç., DEMİRKAN S. K., et al.TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, cilt.0, 2023 (ESCI, Scopus, TRDizin)
23. Diagnostic performance and longitudinal analysis of fungal biomarkers in COVID-19 associated pulmonary aspergillosisER B., ER A. G., GÜLMEZ KIVANÇ D., ŞAHİN T. K., METAN G., SARIBAŞ Z., et al.Heliyon, cilt.9, sa.11, 2023 (SCI-Expanded, Scopus)
24. Acute Loss-of-consciousness in Patient with Relapsing Candidemia and BacteremiaVural A. M., Arslan S., Erol T., İNKAYA A. Ç., Oguz K. K., UZUN Ö.INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, cilt.2, sa.1, ss.52-53, 2020 (ESCI, TRDizin)

1. Nephrotoxicity of piperacillin tazobactam combined with vancomycin Should it be a concernBALCI C., UZUN Ö., ARICI M., AŞÇIOĞLU HAYRAN S., YÜCE D., ÜNAL S.International Conference on Antimicrobial Agents and Chemotherapy/International Congress of Chemotherapy 2015, San Diego, Amerika Birleşik Devletleri, 17 - 21 Eylül 2015
2. NEW ANTIBIOTIC STRATEGY IN FEBRILE NEUTROPENIAUZUN Ö.5th International Eurasian Hematology Congress, Antalya, Türkiye, 15 - 19 Ekim 2014, cilt.38, (Özet Bildiri)
3. Kan kültürlerinden izole edilen Candida türlerinin PNA FISH yöntemiyle hızlı tanımlanmasının konvansiyonel tanımlama yöntemleriyle uyum ve antifungal tedavinin yönlendirilmesine olası etki yönünden değerlendirilmesiDOĞAN AYÇIK Ö., İNKAYA A. Ç., GÜLMEZ KIVANÇ D., UZUN Ö., AKOVA M., ARIKAN AKDAĞLI S.Febril Nötropeni Klavuz Toplantısı, Ankara, Türkiye, 29 - 30 Mart 2014, (Özet Bildiri)
4. Epidemiology of Candida bloodstream infections and antifungal susceptibility profiles 10 year experience with 381 candidaemia episodes in a tertiary care university centreÖZYAVUZ ALP Ş., ARIKAN AKDAĞLI S., GÜLMEZ KIVANÇ D., AŞÇIOĞLU HAYRAN S., UZUN Ö., AKOVA M.European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Londrina, Birleşik Krallık, 31 Mart - 03 Nisan 2012, (Özet Bildiri)
5. Karbapenem dirençli genişletilmiş spektrumlu beta laktamaz salgılayan Escherichia coli izolatıMETAN G., GÜLMEZ KIVANÇ D., UZUN Ö., KOCAGÖZ A. S., HASÇELİK A. G.7. Febril Nötropeni Simpozyumu, Ankara, Türkiye, 23 - 26 Şubat 2006, ss.213, (Özet Bildiri)
6. Infectious complications in patients with hematological malignancies consulted by the infectious diseases tema: a retrospective cohortSAİN GÜVEN G., ÇAKIR B., UZUN Ö.European Congress of Clinical Microbiology and Infectious Deiseases, Glasgow, İngiltere, 10 - 14 Mayıs 2003, (Özet Bildiri)
7. Nötropenik Ateşli Kanaser Hastalarının Tedavi Başarısını Etkileyen Faktörlerin İncelenmesiSAİN GÜVEN G., ÇAKIR B., UZUN Ö., AKOVA M.KLİMİK 2003 XV. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, İstanbul, Türkiye, 31 Mart - 03 Nisan 2003, (Özet Bildiri)
8. COVID-19 Pandemisi Sürecinde Aspergillus PCR Kullanımının İnvaziv Aspergilloz Tanı ve Tedavi Kararı Üzerine Etkisi: Tek Merkezli Retrospektif AraştırmaIŞIK M. C., METAN G., ALP A., GÜLMEZ KIVANÇ D., ARIKAN AKDAĞLI S., UZUN Ö.
9. A retrospective study comparing cefoperazone sulbactam with piperacillin tazobactam as empirical therapy for febrile neutropenia in adults with hematological disordersbitik b., ÖZYAVUZ ALP Ş., ÇALIK BAŞARAN N., AKOVA M., UZUN Ö., ÜNAL S.

1. COVID-19: Etken, Risk Faktörleri, Klinik, Tanı ve TedaviDEĞİRMENCİLER R. F., ÇALIK BAŞARAN N., UZUN Ö.